Intra-Cellular Therapies Other Current Liabilities

As of the most recent data (December 2024), ITCI shows a other current liabilities of $180M. That compares with $110M in the prior-year period — up 61.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ITCI's other current liabilities is now $180M (was $110M) — a 61.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Intra-Cellular Therapies is outperforming or lagging.

Tracking ITCI's other current liabilities over time shows whether Intra-Cellular Therapies is scaling, shrinking, or reshaping that part of the business. The current reading is $180M That compares with $110M in the prior-year period — up 61.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Intra-Cellular Therapies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $180M) with ownership activity and broader fundamentals.

Intra-Cellular Therapies's other current liabilities is $180M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.